EPO906 (epothilone B)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Central Nervous System Neoplasms
Conditions
Central Nervous System Neoplasms, Head and Neck Neoplasms
Trial Timeline
Feb 1, 2004 → Jul 1, 2009
NCT ID
NCT00328458About EPO906 (epothilone B)
EPO906 (epothilone B) is a phase 1 stage product being developed by Novartis for Central Nervous System Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00328458. Target conditions include Central Nervous System Neoplasms, Head and Neck Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00328458 | Phase 1 | Completed |
Competing Products
20 competing products in Central Nervous System Neoplasms